CA2355820A1 - Formulations comprenant des liporegulateurs - Google Patents

Formulations comprenant des liporegulateurs Download PDF

Info

Publication number
CA2355820A1
CA2355820A1 CA002355820A CA2355820A CA2355820A1 CA 2355820 A1 CA2355820 A1 CA 2355820A1 CA 002355820 A CA002355820 A CA 002355820A CA 2355820 A CA2355820 A CA 2355820A CA 2355820 A1 CA2355820 A1 CA 2355820A1
Authority
CA
Canada
Prior art keywords
composition
lipid
propylene glycol
regulating agent
fenofibrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002355820A
Other languages
English (en)
Inventor
John M. Lipari
Dawn M. Raymond
Tom Reiland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2355820A1 publication Critical patent/CA2355820A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une formulation comprenant un liporégulateur dissout dans au moins un ester d'acide gras du propylène-glycol servant de solvant primaire pour ce liporégulateur. Cette formulation peut également intégrer un ou plusieurs émulsifiants.
CA002355820A 1998-12-18 1999-12-15 Formulations comprenant des liporegulateurs Abandoned CA2355820A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21644898A 1998-12-18 1998-12-18
US09/216,448 1998-12-18
PCT/US1999/029696 WO2000037057A2 (fr) 1998-12-18 1999-12-15 Formulations comprenant des liporegulateurs

Publications (1)

Publication Number Publication Date
CA2355820A1 true CA2355820A1 (fr) 2000-06-29

Family

ID=22807109

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002355820A Abandoned CA2355820A1 (fr) 1998-12-18 1999-12-15 Formulations comprenant des liporegulateurs

Country Status (4)

Country Link
EP (1) EP1140036A2 (fr)
JP (1) JP2002532539A (fr)
CA (1) CA2355820A1 (fr)
WO (1) WO2000037057A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372251B2 (en) * 1999-06-11 2002-04-16 Abbott Laboratories Formulations comprising lipid-regulating agents
US6982281B1 (en) 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
EP1395254B1 (fr) * 2001-06-12 2007-04-04 Galephar M/F Composition pharmaceutique orale comprenant un derive de statine
FR2827770B1 (fr) * 2001-07-27 2005-08-19 Gattefosse Ets Sa Composition pharmaceutique a usage oral comprenant un principe actif susceptible de subir un important effet de premier passage intestinal
EP1786414A4 (fr) 2004-08-06 2008-04-09 Transform Pharmaceuticals Inc Nouvelles compositions pharmaceutiques a base de statines et methodes de traitement associees
AU2005314197A1 (en) * 2004-12-06 2006-06-15 Reliant Pharmaceuticals, Inc. Stable compositions of fenofibrate with fatty acid esters
WO2008015959A1 (fr) * 2006-08-01 2008-02-07 Otsuka Pharmaceutical Co., Ltd. Composition pharmaceutique permettant une meilleure absorption d'une substance pharmacologiquement active
JP5186159B2 (ja) * 2006-08-31 2013-04-17 あすか製薬株式会社 フェノフィブラート含有組成物
JP2013047282A (ja) * 2006-08-31 2013-03-07 Aska Pharmaceutical Co Ltd フェノフィブラート含有組成物
EP2351566B1 (fr) * 2008-10-22 2014-12-10 Santen Pharmaceutical Co., Ltd Composition pharmaceutique améliorée en matière d absorption à travers le tractus intestinal
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
EP2400840A4 (fr) * 2009-02-24 2012-08-01 Madeira Therapeutics Formulations de statine liquide
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
WO2016033549A2 (fr) 2014-08-28 2016-03-03 Lipocine Inc. Compositions de (17-ss)-3-oxoandrost-4-èn-17-yl tridécanoate et leurs procédés de préparation et d'utilisation
WO2016033556A1 (fr) 2014-08-28 2016-03-03 Lipocine Inc. Esters de (17-β)-hydroxy-4-androstène-3-one biodisponibles à l'état solide
TW201628625A (zh) 2015-02-06 2016-08-16 英特賽普醫藥品公司 組合療法醫藥組成物
US20180147215A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU210565B (en) * 1990-12-18 1995-05-29 Merrell Dow Pharma Process for production of enhanced bioavailability pharmaceutical coposition containing probucol
WO1995014463A1 (fr) * 1993-11-25 1995-06-01 Taisho Pharmaceutical Co., Ltd. Composition de preparation pharmaceutique a absorption perorale amelioree
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US6201009B1 (en) * 1998-10-30 2001-03-13 Fujirebio Inc. Absorption-enhancing composition for pantothenic acid derivative

Also Published As

Publication number Publication date
WO2000037057A3 (fr) 2000-11-16
JP2002532539A (ja) 2002-10-02
EP1140036A2 (fr) 2001-10-10
WO2000037057A2 (fr) 2000-06-29

Similar Documents

Publication Publication Date Title
US6372251B2 (en) Formulations comprising lipid-regulating agents
MXPA01009840A (es) Nuevas formulaciones que comprenden agentes reguladores de lipido.
US6465011B2 (en) Formulations comprising lipid-regulating agents
CA2355820A1 (fr) Formulations comprenant des liporegulateurs
US6326360B1 (en) Bubbling enteric coated preparations
US6838091B2 (en) Formulations comprising lipid-regulating agents
CA2367995A1 (fr) Nouvelles formules comprenant des agents de regulation des lipides
US20020102301A1 (en) Pharmaceutical solid self-emulsifying composition for sustained delivery of biologically active compounds and the process for preparation thereof
MX2007012124A (es) Formulaciones mejoradas de fenofibrato.
US6719999B2 (en) Formulations comprising lipid-regulating agents
US20040235935A1 (en) Oral pharmaceutical composition containing a statin derivative
US6814977B1 (en) Formulations comprising lipid-regulating agents
US20020040046A1 (en) Novel formulations comprising lipid-regulating agents
US20050192340A1 (en) Simvastatin formulations and methods of making same
US7014864B1 (en) Formulations comprising lipid-regulating agents
JP2011526621A (ja) 経口バイオアベイラビリティが増大したフェノフィブラート製剤
EP1183017A1 (fr) Formulations comprenant des agents regulateurs des lipides

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead